What is Vaxart?
Vaxart is a clinical-stage biotechnology company dedicated to transforming the landscape of vaccine administration. By leveraging a proprietary oral delivery platform, the firm develops pill-based vaccines designed to prevent a range of infectious diseases, including coronavirus, norovirus, and influenza. This innovative approach addresses critical barriers in global health, such as vaccine accessibility and patient compliance, by eliminating the need for traditional needle-based injections. As a key player in the life sciences ecosystem, Vaxart focuses on creating scalable, convenient, and effective immunization solutions that can be easily distributed and administered on a global scale.
How much funding has Vaxart raised?
Vaxart has raised a total of $168.4M across 8 funding rounds:
Series A
$3.3M
Series B
$16.9M
Stock Offering
$26.9M
Multiple Rounds
$21.3M
Stock Offering
$10M
Debt
$90M
Series A (2007): $3.3M with participation from Quantum Technology Partners, Life Science Angels, Sand Hill Angels, National Institutions of Health SBIR, and Bay Partners
Series B (2012): $16.9M led by Care Capital
Stock Issuance/Offering (2014): $26.9M supported by Undisclosed
Stock Issuance/Offering (2019): $3M featuring Undisclosed
Stock Issuance/Offering (2019): $9.3M backed by Undisclosed
Stock Issuance/Offering (2019): $9M with participation from Undisclosed
Stock Issuance/Offering (2020): $10M led by Undisclosed
Debt (2020): $90M supported by RA Capital Management and Invus
Key Investors in Vaxart
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, utilizing its internal TechAtlas think tank to support clinical data-driven investment strategies.
Invus
Invus Group is a New York-based investment firm established in 1985, providing specialized financial advice and strategic consulting services to support long-term growth in its portfolio companies.
Bay Partners
As one of the first venture capital firms in Silicon Valley, Bay Partners leverages nearly 40 years of experience to guide companies from startup to successful liquidity events, including IPOs and M&A transactions.
What's next for Vaxart?
Following the recent strategic financing, Vaxart is well-positioned to scale its research and development operations. The company's roadmap focuses on advancing its lead candidates through clinical trials while optimizing its manufacturing processes for large-scale production. By maintaining a robust balance sheet, Vaxart aims to solidify its market position as a leader in oral vaccine technology. Future growth will likely be driven by strategic partnerships and the continued validation of its platform's efficacy, as the firm seeks to address unmet needs in the global vaccine market and transition from a development-focused entity to a commercial-stage innovator.
See full Vaxart company page
